ISRCTN47723344已完成不适用
Medical Research Council sixth myelomatosis trial for previously untreated patients: ABCM with or without clodronate
Medical Research Council (MRC) (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Aged <75 years
- •2. Myelomatosis defined as having at least two of the following:
- •a. Bone marrow smears or sections showing the presence of a neoplastic plasma cell infiltrate and/or microplasmacytomas
- •b. A paraprotein present in the blood or urine
- •c. Definite lytic bone lesions
- •2. Patients with equivocal myelomatosis are not eligible
- •3. No previous cytotoxic chemotherapy, except in the circumstances defined in the protocol
- •4. Able to tolerate a daily fluid intake of not less than 3 L
- •5. No contraindications to any of the treatment protocols
排除标准
- •Not provided at time of registration.
研究者
相似试验
已完成
不适用
VIIIth myelomatosis trialMyelomatosisMultiple myeloma and malignant plasma cell neoplasmsCancerISRCTN32846751Medical Research Council (MRC) (UK)
已完成
不适用
Myeloma VII - myelomatosis therapy trialeukaemiaCancerLeukaemiaISRCTN66518389Medical Research Council (MRC) (UK)750
已完成
不适用
MYELOMA VIIIth trialeukaemiaCancerLeukaemiaISRCTN52157196Medical Research Council (MRC) (UK)1,000
进行中（未招募）
1 期
A Phase II Clinical Trial in Patients with BRCA defective TumoursAdvanced or metastatic breast or ovarian cancer.MedDRA version: 16.1 Level: LLT Classification code 10028985 Term: Neoplasm breast System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016846-16-GBniversity of Oxford67
已完成
不适用
The GMMG-HD5 trial: bortezomib-based induction prior to high dose therapy and autologous stem cell transplantation followed by lenalidomide-based consolidation and maintenance therapy in patients with multiple myelomaCancerMultiple myelomaISRCTN05745813Heidelberg University (Germany)504